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Objective. New treatment algorithms using tumor necrosis factor (TNF) blockers in early stages of spondyloarthritis (SpA) induce high rates of clinical remission or low disease activity. It could be anticipated that such early intervention strategies in peripheral SpA may induce drug-free remission. We undertook this study to evaluate drug-free clinical remission after induction therapy with golimumab in patients with very early active peripheral SpA, and to identify patient characteristics that predict sustained drug-free remission.
Methods. Eligible patients were age ≥18 years and fulfilled the Assessment of SpondyloArthritis international Society criteria for peripheral SpA. All patients had symptom duration of <12 weeks. Sustained clinical remission was defined as the absence of arthritis, enthesitis, and dactylitis at 2 consecutive major visits, after which treatment was withdrawn. Patients were prospectively followed up to assess the rate of sustained drug-free clinical remission and clinical relapse.
Results. Eighty-two percent of patients (49 of 60) fulfilled sustained clinical remission criteria after a regimen of induction therapy with golimumab. The majority of patients already reached this status at week 24 (n = 30), with an additional 11 and 8 patients at weeks 36 and 48, respectively. All patients had a follow-up period of at least 18 months after drug withdrawal. Fifty-three percent of patients (26 of 49) still have drug-free remission of their disease. Inability to sustain drug-free remission was associated with the presence of psoriasis and polyarticular disease (swollen joint count >5).
Conclusion. Anti-TNF treatment in very early peripheral SpA results in a remarkably high rate of sustained clinical remission. More than 50% of patients continue to have remission of their disease after withdrawal of therapy, which highlights a defined window of opportunity permitting induction of drug-free remission.
Peripheral spondyloarthritis (SpA) represents a common form of SpA that includes psoriatic arthritis (PsA) and nonpsoriatic peripheral SpA (1) with limited therapeutic options. Most patients with peripheral SpA who have symptoms of peripheral arthritis, dactylitis, and/or enthesitis will experience some level of improvement by the intake of nonsteroidal antiinflammatory drugs (NSAIDs), but additional treatment is necessary. Sulfasalazine is the only disease-modifying antirheumatic drug (DMARD) that has been proven to have some level of efficacy in peripheral SpA (2) . The use of biologic therapies has drastically improved clinical responses in peripheral SpA, with approved indications in PsA for tumor necrosis factor (TNF), interleukin-17A (IL-17A), and IL-12/IL-23 inhibitors. In particular, the efficacy of the TNF inhibitors (TNFi) infliximab, etanercept, adalimumab, certolizumab pegol, and golimumab has been demonstrated across the entire SpA spectrum, including ankylosing spondylitis (AS) and PsA (3) (4) (5) (6) (7) (8) (9) (10) (11) (12) .
Over the past decade, several studies have shown improved therapeutic responses in early versus longstanding forms of various rheumatic diseases. In axial SpA, TNFi are also effective in early stages of disease. Hence, studies in patients with nonradiographic axial SpA have demonstrated at least similar, if not better, efficacy responses compared to treatment at a more advanced stage of the disease (7, (13) (14) (15) . Trials in AS have been set up to evaluate the possibility of withdrawal of TNFi. However, in most cases, discontinuation of TNF blockers after achieving a status of sustained low disease activity or remission led to clinical relapse within a few months (16) (17) (18) (19) (20) (21) [25] ).
There are currently no data on the ability to induce drug-free remission in early peripheral SpA, although a fast relapse was observed in patients with longstanding peripheral SpA after TNFi discontinuation (26) . In this study, we tested the window of opportunity hypothesis, a time frame in which the disease is potentially more susceptible to treatment leading to better disease outcome, in very early peripheral SpA by examining the ability to induce drug-free sustained clinical remission after a regimen of induction therapy with golimumab. We explored patient and disease characteristics predicting sustained clinical remission as opposed to clinical relapse after withdrawal of therapy.
PATIENTS AND METHODS
Patients. All included patients were adults newly diagnosed as having active peripheral SpA and fulfilling the Assessment of SpondyloArthritis international Society (ASAS) criteria for peripheral SpA (1, 27) . Active disease was defined as the persistent presence of arthritis, enthesitis, and/or dactylitis and by a visual analog scale (VAS) score of ≥40 mm on both the patient's global assessment of disease activity and the patient's global assessment of pain at both the screening and baseline visits. All subjects had onset of peripheral SpA symptoms (arthritis, enthesitis, dactylitis) ≤12 weeks prior to the screening visit. In patients with concurrent axial SpA symptoms, the peripheral SpA symptoms were the predominant symptoms at study entry based on the investigator's clinical judgment.
Exclusion criteria included serious infections in the previous 4 weeks, history of malignancy in the past 10 years, and a history of significant other severe or uncontrolled diseases. Patients were allowed to be treated with NSAIDs provided that the dose at baseline was stable for 2 weeks. During the trial, tapering of NSAIDs guided by clinical signs and symptoms was allowed and reported. No concomitant DMARD or corticosteroid therapy was allowed, except for patients already being treated for established psoriasis or inflammatory bowel disease (IBD), and provided that the dose was stable 4 weeks before baseline, with the patient having developed signs and symptoms of SpA for the first time. Local corticosteroid treatments for skin psoriasis and local treatments for uveitis were allowed. Treatment with intraarticular corticosteroid injection(s) for peripheral SpA symptoms in the preceding 12 weeks were not allowed.
The study was approved by the Medical Ethics Committee of Ghent University Hospital, and written informed consent was obtained from each patient before study-related procedures were performed. The study was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki.
Study design. Clinical Remission in Peripheral Spondyloarthritis (CRESPA) study. Sixty patients fulfilling the ASAS criteria for peripheral SpA were enrolled in the CRESPA trial, which consisted of a placebo-controlled part, followed by an open-label phase starting at week 24 until week 48. Patients were randomized in a 2:1 ratio (2 golimumab:1 placebo), and 50 mg golimumab or placebo was administered subcutaneously (SC) every 4 weeks through week 20. Multiple scenarios could occur during this study (Figure 1) . Patients who showed sustained disease activity at the end of the placebo-controlled phase (week 24) received 50 mg golimumab every 4 weeks through week 48. Active disease was defined as the presence of clinical arthritis, enthesitis, or dactylitis. In the open-label CRESPA extension part of the study, patients had to develop a clinical relapse after reaching remission or major clinical response at week 48, after which treatment with 50 mg golimumab every 4 weeks was continued for a total of 104 weeks. Clinical evaluations, standard laboratory evaluations including erythrocyte sedimentation rate (ESR) and C-reactive protein (CRP) level, and patient-reported outcomes were evaluated every 3 months according to daily practice guidelines for the treatment of AS and/or PsA with biologic agents.
Sustained clinical remission. If patients had sustained clinical remission of disease, defined by the absence of clinical arthritis, enthesitis, and dactylitis at 2 major consecutive visits planned at weeks 12, 24, 36, and 48, all treatment was stopped. Subsequently, these patients were prospectively followed up to assess the possibility of maintaining drug-free remission. All patients were instructed to call the treating physician's office in case of increasing symptoms between planned visits, and a rheumatologic evaluation was carried out within 3 days. In case of clinical relapse after drug withdrawal, therapy was restarted with 50 mg golimumab every 4 weeks for a total of 104 weeks in the CRESPA extension part of the study. Clinical relapse was defined as the presence of at least 1 swollen joint, as well as the presence of enthesitis or dactylitis, in the context of SpA.
Major clinical response at week 48. If patients did not reach sustained clinical remission at week 48 but were major responders defined as meeting the Peripheral SpA 40% Response Criteria (achieving a PSpARC40 response) (28), they went directly to the CRESPA extension part of the study and received uninterrupted treatment with 50 mg golimumab every 4 weeks for a total of 104 weeks. A PSpARC40 response was defined as ≥40% improvement from baseline in the scores for the patient's global assessment of disease activity and the patient's global assessment of pain (absolute improvement of ≥20 mm or ≥30 mm, respectively) on a 0-100-mm VAS, coupled with ≥40% improvement in at least 1 of the following: 1) both 76-joint swollen joint count (SJC) and 78-joint tender joint count (TJC), 2) total enthesitis count, or 3) dactylitis count.
Nonresponse. Patients who did not reach sustained clinical remission or meet the PSpARC40 criteria at week 48 were considered nonresponders. In these patients, study treatment was discontinued and conventional treatment options available in daily practice were initiated.
Procedures during every visit. Clinically, we determined the 76-joint SJC, the 78-joint TJC, the dactylitis count (scale 0-20), and the enthesitis count including the Maastricht AS Enthesitis Score (scale 0-13) (29) with the addition of the plantar fascia insertion to the calcaneus, quadriceps tendon insertion into the superior pool of the patella, and patellar ligament insertion into the inferior pool of the patella, accounting for a total of 19 entheseal locations. Body surface area affected by psoriasis was also evaluated.
The clinical remission status and the PSpARC40 response (defined previously) were determined as response criteria. Laboratory tests including CRP level and ESR were performed at each visit.
We calculated the proportion of patients reaching a status of clinical remission at weeks 12, 24, 36, and 48, drugfree sustained clinical remission, clinical relapse after reaching remission, major clinical response at week 48, and nonresponse after a regimen of induction therapy with golimumab. We identified patient and disease characteristics predicting a status of drug-free sustained clinical remission or occurrence of relapse after reaching remission. We documented data regarding duration of drug-free interval until recurrence of symptoms.
Statistical analysis. Data were analyzed using SAS software, version 9.4 (SAS Institute). We calculated that a sample size of 60 patients (20 receiving placebo and 40 receiving golimumab) would be needed to provide 80% statistical power and an alpha level of 0.05, based on previous anti-TNF trials that included peripheral SpA (30, 31) . Descriptive statistics were provided as the proportion of patients achieving the following outcomes: a state of clinical remission at weeks 12, 24, 36, and 48, drug-free sustained clinical remission, clinical relapse after reaching remission, major clinical response at week 48, and nonresponse after a regimen of induction therapy with golimumab.
Logistic regression models were applied to estimate the effects of different patient and disease characteristics on the likelihood that patients achieved these outcomes. The following predictors were analyzed at baseline: duration between onset of first symptoms and start of golimumab treatment, age, CRP level, AS Disease Activity Score (ASDAS) (32), Bath Ankylosing Spondylitis Functional Index (BASFI) (33) , Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) (34) , presence of psoriasis, and SJC >5 versus SJC ≤5. A rapid response to treatment, defined as the clinical absence of arthritis, enthesitis, and dactylitis at weeks 4, 8, or 12, was analyzed as a predictor for the different outcomes and compared to patients who achieved this status only after 12 weeks. Estimated odds ratios (ORs) are presented with their corresponding 95% confidence intervals (95% CIs). The time to relapse was correlated with the duration of golimumab treatment by using Spearman's correlation coefficient. Kaplan-Meier curves were created to describe the drugfree remission time. Log rank tests were used to determine if there were differences in the distribution of survival for different subpopulations: those with presence or absence of psoriasis, SJC >5, and HLA-B27 positivity. For all analyses, P values less than 0.05 were considered significant.
RESULTS

Baseline demographic and clinical characteristics.
Sixty patients were enrolled in the study and subsequently randomized to receive treatment with golimumab (n = 40) or placebo (n = 20) from March 2012 to July 2015. The demographic features and disease characteristics of the patients were comparable across both treatment arms and are summarized in Table 1 . The mean symptom duration was 4.4 and 5.2 weeks in the placebo and golimumab arms, respectively. The presence of peripheral arthritis, enthesitis, and dactylitis was observed in 59, 25, and 24, respectively, of the 60 patients. There was only 1 patient with dactylitis as the unique peripheral manifestation. In all other patients with dactylitis and/or enthesitis, there was also concomitant arthritis. The overall median TJC and SJC was 4. The overall number of patients with an SJC >5 at baseline was 14 (23%). Almost all patients were receiving NSAIDs at baseline and had a high NSAID index, with no differences between the 2 treatment groups. None of the included patients were receiving DMARD therapy except for 1 patient who was receiving a stable dose of sulfasalazine for established IBD. No patients were receiving glucocorticoids at screening.
The most frequent extraarticular manifestation was skin and/or nail psoriasis in 23 of the 60 patients, with an overall median disease duration of 4 years. Psoriasis involvement was mild, since all 23 patients had a body surface area affected by psoriasis <5%. Regarding other SpA manifestations, proven Crohn's disease and acute anterior uveitis were present in only 1 patient each, with disease durations of 6.4 years and 0.6 years, respectively. Only 7 of 60 patients reported having experienced inflammatory back pain in their medical history, with a median VAS back pain score of 2 (range 0.0-9.0); nevertheless, 35% of patients (21 of 60) exhibited bone marrow edema of the sacroiliac (SI) joints on magnetic resonance imaging (MRI), fulfilling the ASAS definition of a positive MRI. In patients with a positive MRI of the SI joint, the median VAS back pain score was 2.0, compared to 1.0 in patients without sacroiliitis on MRI (P = 0.597).
Proportion of patients achieving a status of clinical remission, major response, and nonresponse. The results of the first 24 weeks, a double-blind placebo-controlled phase, have already been reported (27) . Forty-nine of the 60 patients (82%) achieved the status of sustained clinical remission at week 48 (Figure 2A ), the majority of whom had already achieved this status at week 24 (n = 30), with an additional 11 and 8 patients at weeks 36 and 48, respectively ( Figure 2B ). Of the 49 patients who achieved sustained clinical remission, only 4 were in the placebo arm, while all other patients were treated with golimumab from baseline or used the rescue arm with golimumab treatment. Ten patients did not reach sustained clinical remission at week 48 but were major responders defined as meeting the PSpARC40, and these patients went directly to the CRESPA extension part of the study to receive uninterrupted treatment with 50 mg golimumab SC every 4 weeks for a total of 104 weeks. One patient was a nonresponder at week 24, and treatment with golimumab was discontinued. In all patients who achieved a status of sustained clinical remission, treatment was stopped to evaluate drugfree remission. All patients had a follow-up period of at least 23 months after treatment discontinuation, with a maximum of 5 years to date. Currently, 53% of these patients (26 of 49) still have clinical drug-free remission, while 47% (23 of 49) had relapse of disease after golimumab discontinuation. The median time to relapse was 31.5 weeks. Reinitiation of golimumab promptly restored clinical remission in all patients with recurrence of disease.
Analyses were performed on different subtypes of peripheral SpA (Table 2) . A rather low percentage of drug-free remission (29.4%) was observed in PsA patients compared to patients with other subtypes of peripheral SpA without psoriasis (Table 2) . Five patients had reactive arthritis. Four of them were HLA-B27 positive, 2 of whom experienced clinical relapse upon treatment withdrawal, while the 1 HLA-B27-negative patient still has drug-free remission. Of interest, in the HLA-B27-positive group (n = 33), a better response to treatment, a higher percentage of patients with sustained clinical remission, and a lower percentage of clinical relapse after treatment withdrawal were observed compared to the HLA-B27-negative group (n = 27).
Description of patients' characteristics at the moment of clinical relapse after drug withdrawal. The majority of patients with relapsing disease were male. Recurrence of disease was characterized by development of arthritis in all 23 patients (see Supplementary Table 1 , available on the Arthritis & Rheumatology web site at http:// onlinelibrary.wiley.com/doi/10.1002/art.40573/abstract), with a median of 3 painful and 2 swollen joints. We observed a similar proportion of entheseal symptoms (35%) and dactylitis (48%) compared to baseline during recurrence of disease. Of these patients, 48% were HLA-B27 positive and 52% had psoriasis. The severity of skin disease 
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during recurrence of disease in these patients was mild and comparable to that at baseline. Severity of joint symptoms was also reflected by substantially increased numerical rating scale scores for both patient's global assessment of disease activity and patient's global assessment of pain. All patients restarted treatment with 50 mg golimumab every 4 weeks, and all regained clinical remission within 12 weeks. Parameters predicting occurrence of drug-free sustained clinical remission and clinical relapse. The estimated odds of sustained drug-free remission was 80% lower for patients with psoriasis (OR 0.2 [95% CI 0.06-0.65], P = 0.008) (Figure 3) . Additionally, in patients with polyarticular disease (SJC >5), the odds of sustained drug-free remission was 83% lower (OR 0.17 [95% CI 0.03-0.84], P = 0.03) compared to patients with oligoarticular disease. In contrast, HLA-B27 positivity was a positive predictor for sustained remission with an estimated OR of 3.68 (95% CI 1.22-11.16) (P = 0.021). Similar findings were observed regarding the predictive value of the same parameters for the outcome of clinical relapse. The OR for clinical relapse in patients with psoriasis was 4.58 (95% CI 1.28-16.36) (P = 0.019), and the OR for clinical relapse in patients with polyarticular disease (SJC >5) was 5.25 (95% CI 0.97-28.57) (P = 0.055). Other parameters, including treatment duration, age, CRP level, ASDAS, BASDAI, BASFI, and rapid response to treatment, were not significantly associated with sustained clinical remission or occurrence of relapse. Time to relapse was not correlated with duration of golimumab treatment (r = 0.24, P = 0.29) as assessed by Spearman's correlation coefficient. Figure 4 depicts the survival distribution for drug-free clinical remission over time for the overall population and for the subgroups with presence or absence of psoriasis, SJC >5, and HLA-B27 positivity. The survival distribution was significantly different for the presence of psoriasis (P = 0.02) and SJC >5 (P = 0.01), while the difference was not significant for HLA-B27 positivity (P = 0.10).
Safety analysis. All patients completed the first 48 weeks and had a follow-up period of at least 18 months upon drug withdrawal or were treated in the CRESPA extension part of the study. Overall, there were no unexpected safety signals or serious adverse events. The most common events (Medical Dictionary for Regulatory Activities preferred terms) were nasopharyngitis and upper respiratory tract infection in both groups. No local injection site reactions were observed. No deaths or malignancies were noted during the study period. No tuberculosis reactivation was observed.
DISCUSSION
This is the first study indicating that drug-free remission is an achievable target in early peripheral SpA in at least 50% of patients. It corroborates and extends our earlier results that initiation of TNF blockade in very early peripheral SpA yields remarkably high rates of clinical remission. In contrast, substantially lower responses are observed in patients with more established forms of the disease (27) . Importantly, the lack of a significant response in placebo-treated patients ruled out the possibility of spontaneous remission. Polyarticular disease or preexisting psoriasis were strong predictors of relapse after drug withdrawal. Collectively, these data establish a novel therapeutic framework in defined subsets of early peripheral SpA.
In contrast to most phase III clinical trials in PsA, our population consisted of patients with very early, mainly oligoarticular and DMARD-naive disease, with preexisting psoriasis as the most prevalent extraarticular manifestation. According to the so-called window of opportunity hypothesis, the immune-mediated inflammatory process underlying peripheral SpA becomes less reversible over time, which could be reflected in changes in therapeutic efficacy. The data presented here underscore the potential of such a strategy in at least half of the patients with peripheral SpA. The immunologic mechanisms underlying the observed inverse relationship between disease duration and ability to induce drug-free remission using TNFi are still unclear. One could anticipate that chronic stages of the disease are marked by increased loss of tolerance, epigenetic modifications, or impaired immunoregulatory pathways. Such mechanisms could account for the distinct drug-free remission rates in the present study as opposed to other studies with more established forms of peripheral SpA. However, the precise time frame in which the disease becomes more refractory to drug withdrawal strategies is still unknown.
With this perspective, it should be underscored that the mean disease duration in our cohort was only 5 weeks.
Previous studies have also aimed to assess the impact of therapy withdrawal in peripheral SpA, but ours is the first to study this in very early peripheral SpA. This difference in disease duration appears to be instrumental in the long-term outcome. Hence, Paramarta et al studied the rate of drug-free remission in longstanding peripheral nonpsoriatic SpA with a mean symptom duration of~7 years (26) . Patients received adalimumab for either 12 weeks (n = 12) or 24 weeks (n = 14) before discontinuing anti-TNF therapy, once the primary end point (an improvement in the patient's global assessment of disease activity) was achieved (35) . At the time point of adalimumab discontinuation, 11 patients (42.3%) had no swollen joints (0-66 SJC), and 14 patients (53.8%) had reached inactive disease status according to the ASDAS. After adalimumab discontinuation, 73.1% had relapse of disease after a mean AE SD 10.0 AE 3.2 weeks (26). The striking difference in relapse DRUG-FREE REMISSION IN EARLY PERIPHERAL SpArate between Paramarta et al's study and our own is most likely due to the difference in symptom duration (7 years in their study versus only 5 weeks in our trial). However, there were also some differences in the entry criteria used. Paramarta et al's trial used the European Spondylarthropathy Study Group criteria (36) and/or the Amor criteria for SpA (37) without fulfilling the criteria for AS or PsA, while in our study all included patients fulfilled the ASAS criteria. Nevertheless, 38 of the 40 patients in Paramarta et al's study also fulfilled the ASAS criteria for peripheral SpA.
Another difference that could have led to a lower relapse rate in our study was the use of more stringent remission criteria to permit anti-TNF treatment withdrawal. These involved the lack of any joint swelling as well as the absence of signs of enthesitis or dactylitis, criteria that exclude patients with unstable remission. In Paramarta et al's trial, anti-TNF therapy was stopped if patients had an improvement in their global assessment of disease activity. Consequently, only 42.3% had a complete disappearance of joint swelling, which was mandatory in our study.
In patients with PsA treated with DMARDs, the possibility of drug-free remission was also examined once patients had continuous disease remission (no musculoskeletal symptoms, no or minimal skin/nail disease) for at least 6 months (38) . The mean disease duration of the examined study group was 6.54 years. A high recurrence rate (76.9%) was observed after treatment discontinuation, which occurred rapidly within 74.50 days on average. Of interest, the median time to relapse after discontinuation of treatment in our trial was 31.5 weeks, which is substantially longer than that observed in more longstanding peripheral SpA and PsA (26, 38) . Consistent with these observations, psoriasis appeared to predict poor outcome in our study as well. Patients with preexisting psoriasis had a significantly greater chance of relapse after therapy withdrawal, after achievement of clinical remission. This could indicate that the disease had progressed to a more chronic stage. Indeed, in our patient group, psoriasis was present for 4 years on average, even though the articular symptoms only appeared within a time frame of less than 3 months. Thus, the existence of psoriasis appears to be an indicator of disease chronicity.
The results of this proof-of-concept study will need to be confirmed in large multicenter studies. In any case, the data reiterate the importance of early recognition and referral from primary care to rheumatologists to permit early induction of remission. Such a strategy results in substantially better outcomes in the majority of patients and drug-free remission in half of patients with peripheral SpA.
